Zynerba Pharmaceuticals

Zynerba Pharmaceuticals to Showcase Cutting-Edge Cannabinoid Therapies for Neuropsychiatric Disorders at ASCP 2023

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced an oral podium presentation and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023), being held May …

Zynerba Pharmaceuticals to Showcase Cutting-Edge Cannabinoid Therapies for Neuropsychiatric Disorders at ASCP 2023 Read More


Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) recently announced two poster presentations at the 18th NFXF International Fragile X Conference, being held July 14-17, 2022, in San Diego, Calif. …

Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference Read More